Single-agent bevacizumab for the management of refractory malignant effusions in heavily pretreated patients with recurrent high-grade serous cancers of the ovary, fallopian tube or peritoneum: results from a single institution. - Chay, W. Y.; Kumar, A.; Hoskins, P. J.; Tinker, A. V. (European Journal of Gynaecological Oncology, 2018)